These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 34919251)

  • 1. Rationale behind using valproic acid for Non-Hodgkin lymphoma: a biomolecular perspective.
    Ridwansyah H; Wijaya I; Bashari MH; Kartamihardja AHS; Hernowo BS
    Eur Rev Med Pharmacol Sci; 2021 Dec; 25(23):7486-7500. PubMed ID: 34919251
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Antitumor activities of valproic acid on Epstein-Barr virus-associated T and natural killer lymphoma cells.
    Iwata S; Saito T; Ito Y; Kamakura M; Gotoh K; Kawada J; Nishiyama Y; Kimura H
    Cancer Sci; 2012 Feb; 103(2):375-81. PubMed ID: 22017376
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Mechanism of inhibiting the cell growth in diffuse large B-cell lymphoma by valproic acid combined with temsirolimus].
    Zheng Z; Zhao Y; Dong LH; Wang L; Cheng S; Zhao WL
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2013 Dec; 21(6):1441-7. PubMed ID: 24370026
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Downregulation of TrkB Expression and Signaling by Valproic Acid and Other Histone Deacetylase Inhibitors.
    Dedoni S; Marras L; Olianas MC; Ingianni A; Onali P
    J Pharmacol Exp Ther; 2019 Sep; 370(3):490-503. PubMed ID: 31308194
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Valproic acid inhibits proliferation of HER2-expressing breast cancer cells by inducing cell cycle arrest and apoptosis through Hsp70 acetylation.
    Mawatari T; Ninomiya I; Inokuchi M; Harada S; Hayashi H; Oyama K; Makino I; Nakagawara H; Miyashita T; Tajima H; Takamura H; Fushida S; Ohta T
    Int J Oncol; 2015 Dec; 47(6):2073-81. PubMed ID: 26497673
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Potentiation of anticancer effect of valproic acid, an antiepileptic agent with histone deacetylase inhibitory activity, by the cyclin-dependent kinase inhibitor P276-00 in human non-small-cell lung cancer cell lines.
    Shirsath N; Rathos M; Chaudhari U; Sivaramakrishnan H; Joshi K
    Lung Cancer; 2013 Nov; 82(2):214-21. PubMed ID: 24051085
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Valproic acid induces apoptosis in chronic lymphocytic leukemia cells through activation of the death receptor pathway and potentiates TRAIL response.
    Lagneaux L; Gillet N; Stamatopoulos B; Delforge A; Dejeneffe M; Massy M; Meuleman N; Kentos A; Martiat P; Willems L; Bron D
    Exp Hematol; 2007 Oct; 35(10):1527-37. PubMed ID: 17697742
    [TBL] [Abstract][Full Text] [Related]  

  • 8. FLT3-ITD-, but not BCR/ABL-transformed cells require concurrent Akt/mTor blockage to undergo apoptosis after histone deacetylase inhibitor treatment.
    Cai D; Wang Y; Ottmann OG; Barth PJ; Neubauer A; Burchert A
    Blood; 2006 Mar; 107(5):2094-7. PubMed ID: 16304046
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Valproic acid induces NET cell growth arrest and enhances tumor suppression of the receptor-targeted peptide-drug conjugate via activating somatostatin receptor type II.
    Sun L; Qian Q; Sun G; Mackey LV; Fuselier JA; Coy DH; Yu CY
    J Drug Target; 2016; 24(2):169-77. PubMed ID: 26211366
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The synergistic effects of valproic acid and fluvastatin on apoptosis induction in glioblastoma multiforme cell lines.
    Chang YL; Huang LC; Chen YC; Wang YW; Hueng DY; Huang SM
    Int J Biochem Cell Biol; 2017 Nov; 92():155-163. PubMed ID: 29017950
    [TBL] [Abstract][Full Text] [Related]  

  • 11. An overview of investigational Histone deacetylase inhibitors (HDACis) for the treatment of non-Hodgkin's lymphoma.
    Apuri S; Sokol L
    Expert Opin Investig Drugs; 2016 Jun; 25(6):687-96. PubMed ID: 26954526
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Induction of neurotrophic and differentiation factors in neural stem cells by valproic acid.
    Almutawaa W; Kang NH; Pan Y; Niles LP
    Basic Clin Pharmacol Toxicol; 2014 Aug; 115(2):216-21. PubMed ID: 24460582
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Rituximab: a review of its use in non-Hodgkin's lymphoma and chronic lymphocytic leukaemia.
    Plosker GL; Figgitt DP
    Drugs; 2003; 63(8):803-43. PubMed ID: 12662126
    [TBL] [Abstract][Full Text] [Related]  

  • 14. HDAC inhibitor valproic acid protects heart function through Foxm1 pathway after acute myocardial infarction.
    Tian S; Lei I; Gao W; Liu L; Guo Y; Creech J; Herron TJ; Xian S; Ma PX; Eugene Chen Y; Li Y; Alam HB; Wang Z
    EBioMedicine; 2019 Jan; 39():83-94. PubMed ID: 30552062
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Biochemical, molecular and epigenetic mechanisms of valproic acid neuroprotection.
    Monti B; Polazzi E; Contestabile A
    Curr Mol Pharmacol; 2009 Jan; 2(1):95-109. PubMed ID: 20021450
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Resistance after chronic application of the HDAC-inhibitor valproic acid is associated with elevated Akt activation in renal cell carcinoma in vivo.
    Juengel E; Makarević J; Tsaur I; Bartsch G; Nelson K; Haferkamp A; Blaheta RA
    PLoS One; 2013; 8(1):e53100. PubMed ID: 23372654
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Downregulation of Nrf2 by the combination of TRAIL and Valproic acid induces apoptotic cell death of TRAIL-resistant papillary thyroid cancer cells via suppression of Bcl-xL.
    Cha HY; Lee BS; Chang JW; Park JK; Han JH; Kim YS; Shin YS; Byeon HK; Kim CH
    Cancer Lett; 2016 Mar; 372(1):65-74. PubMed ID: 26721202
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Histone deacetylase inhibitor potentiated the ability of MTOR inhibitor to induce autophagic cell death in Burkitt leukemia/lymphoma.
    Dong LH; Cheng S; Zheng Z; Wang L; Shen Y; Shen ZX; Chen SJ; Zhao WL
    J Hematol Oncol; 2013 Jul; 6():53. PubMed ID: 23866964
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The histone deacetylase inhibitor valproic acid lessens NK cell action against oncolytic virus-infected glioblastoma cells by inhibition of STAT5/T-BET signaling and generation of gamma interferon.
    Alvarez-Breckenridge CA; Yu J; Price R; Wei M; Wang Y; Nowicki MO; Ha YP; Bergin S; Hwang C; Fernandez SA; Kaur B; Caligiuri MA; Chiocca EA
    J Virol; 2012 Apr; 86(8):4566-77. PubMed ID: 22318143
    [TBL] [Abstract][Full Text] [Related]  

  • 20. In vitro and in vivo interactions between the HDAC6 inhibitor ricolinostat (ACY1215) and the irreversible proteasome inhibitor carfilzomib in non-Hodgkin lymphoma cells.
    Dasmahapatra G; Patel H; Friedberg J; Quayle SN; Jones SS; Grant S
    Mol Cancer Ther; 2014 Dec; 13(12):2886-97. PubMed ID: 25239935
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.